Press Releases

CRANBURY, N.J., Feb. 4, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 18th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 18th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf Astoria in New York […]

Palatin Technologies Reconnect Study Logo CRANBURY, N.J., Dec. 10, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical

Palatin Technologies Reconnect Study Logo CRANBURY, N.J., Nov. 12, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2015.  Recent Highlights Bremelanotide development for Female

CRANBURY, N.J., Nov. 10, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2016 operating results on Thursday, November 12, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November

CRANBURY, N.J., Sept. 28, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that a poster entitled “Conditional cardiomyocyte-restricted Corin KO mice demonstrate enhanced cardiac hypertrophy and pro-fibrotic gene activation in response to

CRANBURY, N.J., Sept. 21, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.  Fiscal Year Ended June 30, 2015 and Recent

CRANBURY, N.J., Sept. 21, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the Company and Gedeon Richter (Richter) mutually and amicably agreed to terminate the license and collaboration agreement for bremelanotide

CRANBURY, N.J., Sept. 16, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year end 2015 operating results on Monday, September 21, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on

CRANBURY, N.J., Aug. 18, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin’s lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD). The approval of flibanserin (under development

CRANBURY, N.J. and FARMINGTON, Conn., July 6, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has closed on a private placement of Series E warrants to purchase 21,917,808 shares of